At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Vonoprazan-based Therapy Versus Standard Regimen for Helicobacter Pylori Infection Management
In Brief
A Phase 4 clinical trial evaluating standard Clarithromycin triple therapy, Vonoprazan triple therapy, and 1 other intervention for Helicobacter Pylori Infection. Completed, enrolled 132 participants across 1 site.
Detailed Summary
Appropriately, half of the global population is infected with H. pylori, and it is now recognized that it causes at least 95% of all gastric cancers. Currently, the main challenge in the field of H. pylori infection is the rapidly increasing antibiotic resistance worldwide, which is causing a decline in the effectiveness of currently available eradication regimens. The aim of the study is to assess the safety and efficacy of different H. pylori vonoprazan-based regimens compared to the commonly used standard triple therapy composed of Clarithromycin, Amoxicillin, and Proton pump inhibitor to eradicate H. pylori infection in treatment-naive patients through the determination of each regimen eradication rate and reported safety profile
Study Details
Timeline
Interventions
Oral administration of proton pump inhibitor standard or double dose twice daily, clarithromycin 500 mg twice daily and, Amoxicillin1g twice daily for 14 days
Oral administration of Vonoprazan 20mg twice daily, clarithromycin 500 mg twice daily, and, Amoxicillin1g twice daily for 14 days
Oral administration of Vonoprazan 20mg twice daily and, Amoxicillin1g three times daily for 14 days